Hidradenitis Suppurativa

Table of Contents

  1. What Hidradenitis Suppurativa Is
  2. Clinical Features and Hurley Staging
  3. Pathophysiology
  4. Metabolic and Systemic Associations
  5. Mild Treatment (Hurley Stage I)
  6. Moderate Treatment (Hurley Stage II)
  7. Severe Treatment (Hurley Stage III)
  8. Quality of Life and Mental Health
  9. Key Research Papers
  10. Connections
  11. Featured Videos

What Hidradenitis Suppurativa Is

Hidradenitis suppurativa (HS) — also called acne inversa — is a chronic, painful inflammatory skin disease affecting the hair follicles in areas rich in apocrine glands: the armpits, groin, perianal area, buttocks, and under the breasts. Despite its name suggesting sweat gland involvement, HS is now understood to originate in the hair follicle, not the apocrine gland itself — the glands are involved secondarily.

HS is severely underdiagnosed, with an average diagnostic delay of 7–10 years. Many patients are told they have "boils" or "infected ingrown hairs" and cycle through general practitioners, surgeons, and emergency rooms before reaching a dermatologist who recognizes the condition. Estimates of how common it is range from about 0.1% of people (US studies of routine health records) to 1% or more (European studies, which also count people who were never diagnosed) — a more than tenfold gap that a 2020 review calls a high priority to resolve. In North American and European patients it is about three times more common in women than men, while in South Korean patients the ratio is reversed (about one woman for every two men). Onset typically occurs after puberty, usually in the teens to mid-30s.

HS has one of the highest rates of pain, depression, and quality-of-life impairment of any dermatological condition. The combination of chronic pain, scarring, drainage, and odor significantly impacts relationships, employment, and daily functioning.

Clinical Features and Hurley Staging

HS presents as recurrent, painful nodules and abscesses in characteristic locations. Unlike a typical abscess caused by a bacterial infection, HS abscesses are sterile initially — bacteria colonize secondarily. Key features:

Hurley Staging (most widely used staging system):

Pathophysiology

The central event in HS is follicular occlusion — the opening (infundibulum) of the hair follicle becomes blocked, causing the follicle to dilate and eventually rupture. The rupture releases keratin, bacteria, and follicular contents into the surrounding dermis, triggering an intense inflammatory response.

This process is NOT a primary infection. Bacterial cultures of early HS lesions are often sterile or show only skin commensal bacteria. Antibiotics help not by eradicating infection but by reducing inflammatory bacterial signals (particularly from Staphylococcus epidermidis and Cutibacterium acnes). This distinction matters — HS does not respond to antibiotic courses the way a typical infection does, and treating it as simple cellulitis or a boil leads to inappropriate management.

Key pathophysiological elements:

Metabolic and Systemic Associations

HS is increasingly recognized as a systemic inflammatory disease, not just a skin condition:

Mild Treatment (Hurley Stage I)

For mild disease with isolated nodules and abscesses:

Moderate Treatment (Hurley Stage II)

For recurrent disease with sinus tract formation:

Severe Treatment (Hurley Stage III)

For advanced disease with diffuse involvement:

Quality of Life and Mental Health

HS consistently ranks among the skin diseases with the greatest impact on quality of life — comparable to or worse than psoriasis, eczema, and many other chronic skin conditions. This is not surprising given the combination of:

Rates of depression (up to 43%) and anxiety are significantly elevated in HS patients. Suicide ideation rates are also higher than in the general population, and a 2020 review of HS epidemiology reports that completed suicide rates in people with HS are more than double those in people without it. Mental health screening and referral are described as a routine part of HS care. Patient support organizations (HS Foundation, HS Warriors) offer community and educational resources.

Important patient education points: HS is not caused by poor hygiene, it is not contagious, and it is not your fault. It is a complex genetic-immune disease that requires comprehensive management, not just better washing habits.

Key Research Papers

Key peer-reviewed studies on hidradenitis suppurativa. Each PMID link opens the study on PubMed.

  1. Jemec GBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158-164. — PubMed PMID: 22236226
  2. Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2009;23(9):985-998. — PubMed PMID: 19682181
  3. Saunte DM, Boer J, Stratigos A, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Br J Dermatol. 2015;173(6):1546-1549. — PubMed PMID: 26198191
  4. Gulliver W, et al. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord. 2016;17(3):343-351. — PubMed PMID: 26831295
  5. Schlapbach C, et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011;65(4):790-798. — PubMed PMID: 21641076
  6. Ingram JR. The epidemiology of hidradenitis suppurativa. Br J Dermatol. 2020;183(6):990-998. — PubMed PMID: 32880911
  7. Gener G, Canoui-Poitrine F, Revuz JE, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology. 2009;219(2):148-154. — PubMed PMID: 19590173
  8. Zouboulis CC, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization — systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol. 2019;33(1):19-31. — PubMed PMID: 30176066
  9. Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60(4):539-561. — PubMed PMID: 19293006
  10. Kimball AB, Okun MM, Williams DA, et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N Engl J Med. 2016;375(5):422-434. — PubMed PMID: 27518661
  11. Brocard A, Knol AC, Khammari A, Dréno B. Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study. Dermatology. 2007;214(4):325-327. — PubMed PMID: 17460404
  12. Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401(10378):747-761. — PubMed PMID: 36746171
  13. Kimball AB, Jemec GBE, Sayed CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet. 2024;403(10443):2504-2519. — PubMed PMID: 38795716

Curated PubMed topic searches:

  1. PubMed: Adalimumab for HS
  2. PubMed: HS pathogenesis
  3. PubMed: HS and metabolic syndrome
  4. PubMed: Surgical treatment
  5. PubMed: Antibiotic treatment
  6. PubMed: Quality of life and HS
  7. PubMed: HS and Crohn's disease
  8. PubMed: Secukinumab for HS

Back to Table of Contents

Connections

Back to Table of Contents